1. Factors affecting the efficacy and safety of docetaxel combined with platinum in the treatment of advanced non-small cell lung cancer
   FengLi Wang et al, 2021, Expert Review of Clinical Pharmacology CrossRef
2. The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma
   Jong Hyun Choi et al, 2019, Tuberculosis and Respiratory Diseases CrossRef
3. Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non–Small-cell Lung Cancer: A TRAIL Trial
   Cheol-Kyu Park et al, 2017, Clinical Lung Cancer CrossRef
4. A review of relative dose intensity and survival in patients with metastatic solid tumors
   Laura J. Havrilesky et al, 2015, Critical Reviews in Oncology/Hematology CrossRef
5. Efficacy and safety of docetaxel plus oxaliplatin as a first‐line chemotherapy in patients with advanced or metastatic non‐small cell lung cancer
   Heejung Ban et al, 2014, Thoracic Cancer CrossRef
6. Phase I dose-escalation study of aflibercept plus docetaxel in nasopharyngeal carcinoma and other solid tumors
   Yan Huang et al, 2014, Future Oncology CrossRef
7. Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer
   K Shitara et al, 2014, British Journal of Cancer CrossRef